Can We Reverse Aging? The State of Science in 2026, Without the Hype

Every few months, the same headline appears in a new variation: 'Scientists have reversed aging'. An old mouse that restored its black fur, a drug that doubled the lifespan of worms, a 47-year-old billionaire injecting himself with the plasma of his 18-year-old son and declaring he lowered his biological age by five years. The headlines are dizzying, and it's easy to believe the revolution is already here.

A broad review published by the New York Times on May 17, 2026, does something rare in a field full of excitement: it takes a step back and calmly asks, can we truly reverse aging, or are we confusing the lab with the headline? This is neither a cynical article nor a marketing piece. It is an honest attempt to paint the state of science as it is in 2026: real progress, enormous funding, and still no working pill.

What does 'reversing aging' even mean?

Before arguing whether it's possible, it's important to distinguish between two things that are constantly mixed up:

• Slowing aging, causing the body to age more slowly. Stretching the line of functional decline. This we already know how to do, through lifestyle, physical activity, and nutrition.
• Reversing aging, returning cells and tissues to a younger state than they are now. Turning the clock back, not just slowing it. This is the real dream, and this is the part that is still mostly experimental.

Most of the exciting headlines deal with the second category, but most of the strong evidence belongs to the first. This is the central gap that the NYT review tries to expose. When a billionaire claims to have lowered his biological age, he is usually talking about an improvement in health markers, not a reversal of fundamental cellular aging.

The scientific definition of aging has coalesced around what are called the 'hallmarks of aging': DNA damage, telomere shortening, epigenetic changes, loss of proteostasis, disrupted nutrient sensing, poor mitochondrial function, accumulation of zombie cells, and chronic inflammation. Each research stream tries to attack one or more of these hallmarks.

The Four Major Streams: Where the Science Really Stands

The review maps the field into four central directions, and this is perhaps its most important contribution. Instead of 'one big revolution', there are several separate fronts, each at a different stage of maturity.

1. Partial Reprogramming, Yamanaka Factors

This is the direction closest to the word 'reversal' in the literal sense. In 2006, Shinya Yamanaka discovered that four genes (known as OSKM factors, or Yamanaka factors) can return a mature cell to an embryonic stem cell state. The question that ignited the field: Can a cell be returned to its epigenetic youth without erasing its identity?

In mouse studies, controlled doses of these factors returned tissues to a younger profile, restored vision after optic nerve damage, and healed tissues faster. In 2026, companies like Altos Labs and Retro Biosciences are advancing the technology towards first human trials, often for specific eye diseases where the risk is local. But the real danger is clear: too strong reprogramming turns cells into uncontrolled stem cells, meaning cancer. This is the most exciting and the most dangerous direction simultaneously.

2. Senolytics, Eliminating Zombie Cells

Zombie cells (senescent cells) are cells that have stopped dividing but refuse to die, instead secreting inflammatory substances that poison the environment. As we age, they accumulate. Senolytic drugs try to eliminate them in a targeted manner.

In mice, eliminating zombie cells extended healthspan and reversed aging symptoms. In humans, the combination of dasatinib and quercetin is in clinical trials for diseases like pulmonary fibrosis and kidney disease. The results are mixed: encouraging signs, but still no definitive proof that they extend lifespan or rejuvenate healthy humans. This is a promising direction that needs more human evidence.

3. Metabolic Interventions, Rapamycin, Metformin, GLP-1

This is perhaps the direction with the strongest evidence base, and at the same time the most 'boring' from a media perspective. Rapamycin is the only drug that has consistently extended lifespan in a variety of species, including mammals, by inhibiting the mTOR pathway. In humans, it is in trials for low doses, and the community is cautious due to side effects on the immune system.

Metformin, an old and cheap diabetes drug, is at the center of the flagship TAME trial, which aims to test whether it delays age-related diseases in healthy humans. GLP-1 drugs (Ozempic and its peers) have surprised the field: beyond weight loss, they show anti-inflammatory signals and protection for the heart and brain. But they also cause muscle mass loss, highlighting that there is no free lunch.

4. Epigenetic Clocks, The Measurement Tool

You can't reverse something you can't measure. Epigenetic clocks like Horvath, PhenoAge, and GrimAge measure biological age through DNA methylation patterns. They have become the standard by which researchers test whether an intervention 'rejuvenates' someone.

But the NYT warns: An epigenetic clock is a correlation, not necessarily a cause. A decrease in the clock reading does not necessarily prove that actual lifespan has increased. The tool is excellent for research, but it has also become a marketing engine for companies selling biological age tests directly to consumers.

The Billion-Funded Longevity Boom

One of the things that has made the field so noisy is the money. The review describes an unprecedented wave of funding:

• Altos Labs, raised about $3 billion, funded in part by Jeff Bezos, and recruited Nobel laureates to study reprogramming.
• Retro Biosciences, funded by Sam Altman, focuses on reprogramming and extending healthspan.
• Calico, Alphabet's (Google) subsidiary that has been operating in relative quiet for over a decade, with few published results.

This money accelerates real research, but also creates pressure for headlines. When a billionaire funds a field, he expects a media return, and this biases the field's discourse towards being overly optimistic. The NYT distinguishes between the science in the labs (cautious, slow, controlled) and the marketing that wraps it (exciting, accelerated, sometimes disconnected).

What is Truly Promising vs. What is Inflated?

This is the heart of the article, and the distinction the Israeli reader most needs:

• Truly promising: Partial reprogramming for targeted diseases, low-dose rapamycin, senolytics for specific diseases, and the use of epigenetic clocks as a research tool.
• Mostly inflated: Young blood transfusions, most 'stacks' of expensive supplements, biological age tests sold as 'proof' of rejuvenation, and any promise that a single pill will reverse aging in healthy humans within the next decade.

The dividing line is simple: What has worked in humans, in a controlled trial, with a real clinical endpoint, versus what has worked in a mouse or in a cell in a dish. Most of the hype is born from the unjustified leap from mouse to human.

Should I Wait for the Pill, or Act Now?

This is the practical question. The review's answer is sobering but not discouraging. Until the science matures, here is what can be done today, backed by strong evidence:

1. Regular physical activity, the intervention closest to a 'miracle drug' that exists. Resistance training preserves muscle, cardio preserves the heart and brain. It affects almost all hallmarks of aging simultaneously.
2. Quality nutrition and avoidance of excess calories, moderate caloric restriction and fasting intervals activate autophagy, the same pathway that drugs try to mimic.
3. Quality sleep, 7 to 9 hours. Sleep clears brain waste and allows DNA repair.
4. If you have a specific disease, talk to a doctor about whether a metabolic drug like metformin is relevant to your condition, and not as a self-experiment.
5. Caution with expensive supplements, don't pay thousands of shekels a month for stacks not proven in humans. The money is better spent on a gym membership and quality food.

In other words: The only intervention proven today to slow aging in humans is lifestyle, not a miracle molecule.

The Broader Perspective

The question 'can we reverse aging' is actually two questions. Is it possible in principle? Here the answer is more positive than ever: mice rejuvenated by reprogramming, zombie cells eliminated, clocks turned back. The biology of aging is not as one-directional as we thought. Is it possible for me, today, safely? Here the answer is still no, and anyone promising otherwise is selling you something.

The lesson of the review is not cynical but balanced: the field is real, advancing rapidly, and worthy of cautious excitement. But between a headline about a mouse and an approved treatment for humans, there is a long road, paved with quietly failing trials. Scientific patience is not a weakness; it is what will distinguish a real revolution from a bubble.

And perhaps this is the most important point: while we wait for the science to mature, the best intervention is already in our hands, and it's free. Movement, sleep, and real food will measurably rejuvenate you, today, without a pill and without a billion dollars.

References:
The New York Times - Can We Reverse Aging?